Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

JHOP - October 2021 Vol 11, No 5

Editorial
Case Reports
Original Article
Review Article
FDA Oncology Update
Editorial
Urine Alkalinization and Methotrexate Clearance: Are These Key to Safe Administration of High-Dose Methotrexate?
Joseph Bubalo, PharmD, BCPS, BCOP
Read More
Case Reports
Successful Treatment of Nivolumab plus Ipilimumab–Mediated Pure Red-Cell Aplasia and Diabetes with Cyclosporine
Parikshit Padhi, MD, MBBS; Traci M. White, PharmD, PhC, BCGP; Neslihan Cetin, MD
Read More
Original Article
Outcomes of Pharmacist-Provided Telehealth Services in an Ambulatory Oncology Clinic During the COVID-19 Pandemic
Colleen Bohnenkamp, PharmD, BCOP, BCPS; Grace A. Martin, PharmD, BCOP; Laure Dubois, PharmD, BCOP; Olivia Fahey, PharmD, BCOP; Jade Hefler, PharmD
Read More
Tolerance of Oral Targeted Therapies in Patients with Metastatic Renal-Cell Carcinoma and Renal Impairment
Jessica McKernan, PharmD, BCOP; Laura Schmidt, PharmD, BCOP; Melissa Rhoades, PharmD, BCOP
Read More
Efficacy of an Enteral Urine Alkalinization Strategy During Intravenous Sodium Bicarbonate Shortage in Patients with Cancer Receiving High-Dose Methotrexate
Christopher Sinoimeri, PharmD; Matthew Lei, PharmD, BCOP; Stephanie Monaco, PharmD, BCOP; Uvette Lou, PharmD, BCOP
Read More
Review Article
Recent Targeted Therapies Approved for the Treatment of Patients with Urothelial Carcinoma
Bojana Stevich-Heemer, MS, PharmD, MEd, BCOP
Read More
FDA Oncology Update
Online First
Tivdak First Antibody–Drug Conjugate FDA Approved for Recurrent or Metastatic Cervical Cancer
Read More
Online First
Exkivity Novel Oral Targeted Therapy Approved for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations
Read More
Online First
Welireg FDA Approved for 3 Tumor Types Associated with von Hippel-Lindau Disease
Read More
Online First
Rezurock Novel Oral Therapy FDA Approved for Chronic Graft-Versus-Host Disease
Read More
Online First
Jakafi a New Treatment Option for Chronic Graft-Versus-Host Disease
Read More
Online First
Cabometyx Receives FDA Approval for Differentiated Thyroid Cancer
Read More
Brukinsa Approved for Marginal-Zone Lymphoma and for Waldenström’s Macroglobulinemia
Read More
Online First
Jemperli Another Therapy Approved for Patients with dMMR Recurrent or Advanced Solid Tumors
Read More
Online First
Lenvima plus Keytruda a New Combination Approved for Advanced Renal-Cell Carcinoma
Read More
© Amplity Health. All rights reserved.